Evidence map›Paper›PMID 36207308›Full record

ArticleNature communications2022

Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.

Edward M Kennedy, Agnieszka Denslow, Jacqueline Hewett, Lingxin Kong, Ana De Almeida, Jeffrey D Bryant, Jennifer S Lee, Judy Jacques, Sonia Feau, Melissa Hayes and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Pooled it
  2. Review
  3. Review
  4. Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 1 institution in 1 country.

Edward M KennedyOncorus, Inc., Cambridge, MA, USA. matt.kennedy@oncorus.com.ORCID 0000-0002-2817-4809
Agnieszka DenslowOncorus, Inc., Cambridge, MA, USA.
Jacqueline HewettOncorus, Inc., Cambridge, MA, USA.
Lingxin KongOncorus, Inc., Cambridge, MA, USA.
Ana De AlmeidaOncorus, Inc., Cambridge, MA, USA.
Jeffrey D BryantOncorus, Inc., Cambridge, MA, USA.
Jennifer S LeeOncorus, Inc., Cambridge, MA, USA.
Judy JacquesOncorus, Inc., Cambridge, MA, USA.
Sonia FeauOncorus, Inc., Cambridge, MA, USA.
Melissa HayesOncorus, Inc., Cambridge, MA, USA.
Elizabeth L McMichaelOncorus, Inc., Cambridge, MA, USA.
Daniel WambuaOncorus, Inc., Cambridge, MA, USA.
Terry FarkalyOncorus, Inc., Cambridge, MA, USA.
Amal A RahmehOncorus, Inc., Cambridge, MA, USA.
Lauren HerschelmanOncorus, Inc., Cambridge, MA, USA.
Danielle DouglasOncorus, Inc., Cambridge, MA, USA.
Jacob SpinaleOncorus, Inc., Cambridge, MA, USA.
Sanmit AdhikariOncorus, Inc., Cambridge, MA, USA.
Jessica DeterlingOncorus, Inc., Cambridge, MA, USA.
Matt ScottOncorus, Inc., Cambridge, MA, USA.
Brian B HainesOncorus, Inc., Cambridge, MA, USA.
Mitchell H FinerOncorus, Inc., Cambridge, MA, USA.
Ted T AshburnOncorus, Inc., Cambridge, MA, USA.
Christophe QuévaOncorus, Inc., Cambridge, MA, USA.
Lorena LernerOncorus, Inc., Cambridge, MA, USA.
Oncor (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic effectiveness of oncolytic viruses (OVs) delivered intravenously is limited by the development of neutralizing antibody responses against the virus. To circumvent this limitation and to enable repeated systemic administration of OVs, here we develop Synthetic RNA viruses consisting of a viral RNA genome (vRNA) formulated within lipid nanoparticles. For two Synthetic RNA virus drug candidates, Seneca Valley virus (SVV) and Coxsackievirus A21, we demonstrate vRNA delivery and replication, virus assembly, spread and lysis of tumor cells leading to potent anti-tumor efficacy, even in the presence of OV neutralizing antibodies in the bloodstream. Synthetic-SVV replication in tumors promotes immune cell infiltration, remodeling of the tumor microenvironment, and enhances the activity of anti-PD-1 checkpoint inhibitor. In mouse and non-human primates, Synthetic-SVV is well tolerated reaching exposure well above the requirement for anti-tumor activity. Altogether, the Synthetic RNA virus platform provides an approach that enables repeat intravenous administration of viral immunotherapy.

Indexed as

NeoplasmsOncolytic VirotherapyOncolytic VirusesPicornaviridaeAnimalsAntibodies, NeutralizingImmunotherapyLiposomesMiceNanoparticlesRNA, ViralTumor MicroenvironmentAntibodies, NeutralizingLipid NanoparticlesLiposomesRNA, Viral

Identifiers

PMID36207308
PMCPMC9546900
OpenAlexW4303183557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.